Consequently, little attention has been drawn to the issue of RTIs in patients receiving TNF antagonists despite observations that LRTIs, and specifically pneumonia, are among the most common serious infections associated with the use of these agents.3,25. The gene discussed is TNF; the disease is susceptibility to pneumonia measurement.